The research support for the ENCOMPASS integrated treatment intervention is based on the results of three controlled clinical trials conducted by a team of researchers and clinicians at the University of Colorado, led by Dr. Paula Riggs. The 498 adolescents and young adults (ages 13-21) who participated in these studies had an average of 3 substance abuse or dependence diagnoses and 2-3 co-occurring psychiatric disorders (conduct disorder, depression, anxiety, ADHD). Taken together results of these studies showed superior psychiatric and substance treatment outcomes with 16 weeks of integrated treatment (individual CBT, medication) than have been reported for separate or sequential mental health and substance treatment approaches. Clinically relevant outcomes include:
- Substance Outcomes: Treatment compliance, treatment completion (75%-85% completed the studies), and reduction in drug use was comparable or greater than that reported for other evidence-based substance treatments in young people with less severe substance abuse and psychopathology.
- Mental Health Outcomes: Remission or reduction in psychiatric symptoms including conduct/behavior problems (> 50%); ADHD (> 45%); depression (> 60% remission) were comparable or greater than that reported for pharmacotherapy or psychotherapy interventions for these disorders in youths who do not have substance use disorders.
- Longer-term Post-treatment Outcomes: A one-year post-treatment follow-up study showed sustained treatment gains or continued improvement in conduct problems, psychiatric symptoms including depression, and reduction in drug use during the year following treatment.